Guardant Health Q3 EPS Estimate Lowered by Leerink Partnrs

Guardant Health, Inc. (NASDAQ:GH) – Research analysts at Leerink Partnrs lowered their Q3 2025 EPS estimates for shares of Guardant Health in a report released on Monday, April 21st. Leerink Partnrs analyst P. Souda now forecasts that the company will post earnings per share of ($0.76) for the quarter, down from their previous estimate of ($0.75). The consensus estimate for Guardant Health’s current full-year earnings is ($2.90) per share. Leerink Partnrs also issued estimates for Guardant Health’s Q4 2026 earnings at ($0.70) EPS and FY2027 earnings at ($2.13) EPS.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.15). Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The business had revenue of $201.81 million during the quarter, compared to the consensus estimate of $192.50 million.

Other research analysts have also recently issued reports about the stock. Morgan Stanley lifted their price objective on shares of Guardant Health from $42.00 to $52.00 and gave the company an “overweight” rating in a research note on Thursday, March 6th. Stephens restated an “overweight” rating and issued a $55.00 price target on shares of Guardant Health in a research report on Wednesday, March 26th. Canaccord Genuity Group lifted their price objective on Guardant Health from $42.00 to $60.00 and gave the stock a “buy” rating in a research note on Monday, February 24th. JPMorgan Chase & Co. boosted their price target on Guardant Health from $50.00 to $55.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. Finally, Piper Sandler upped their price objective on shares of Guardant Health from $34.00 to $50.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. Twenty equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $49.00.

Guardant Health Trading Up 4.4 %

Shares of GH stock opened at $45.73 on Wednesday. The stock has a market cap of $5.64 billion, a P/E ratio of -12.85 and a beta of 1.45. Guardant Health has a 1 year low of $16.77 and a 1 year high of $50.89. The stock has a 50 day simple moving average of $43.39 and a 200 day simple moving average of $36.82.

Institutional Investors Weigh In On Guardant Health

Institutional investors have recently bought and sold shares of the business. Oppenheimer & Co. Inc. bought a new stake in shares of Guardant Health in the first quarter worth about $442,000. Canton Hathaway LLC purchased a new position in Guardant Health in the 1st quarter worth about $353,000. Janney Montgomery Scott LLC purchased a new stake in shares of Guardant Health in the first quarter valued at approximately $232,000. Fifth Third Bancorp bought a new stake in shares of Guardant Health in the first quarter valued at about $279,000. Finally, Handelsbanken Fonder AB boosted its stake in shares of Guardant Health by 13.1% during the first quarter. Handelsbanken Fonder AB now owns 32,741 shares of the company’s stock valued at $1,395,000 after purchasing an additional 3,800 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.